Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orenitram in Pulmonary Arterial Hypertension (FREEDOM DR)
NCT00760916Phase 3Withdrawn
- Sponsor
- United Therapeutics Corporation
- Start
- Dec 2008
- Primary completion
- Jan 2009
- Modality
- Orthosteric Ligands
- Countries
- 3
01
Overview
A Phase 3 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Planned start Dec 2008; status: withdrawn.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT00760916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00760916.